BIOIMPACT CAPITAL LLC
Q2 2023 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001687078
· CRD 309865
· SEC-registered investment adviser
$496.6M Reported Value Total
BIOIMPACT CAPITAL LLC reports 9 total accounts under management (AUM). There are 9 discretionary accounts valued at $1,986,654,826, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
4 funds
· $2.0B gross asset value
Other: $1.8B · Hedge Fund: $138.3M
Source: Form ADV filed 2022-11-17
Reported value
$496.6M
Quarter over quarter
+13.2%
Holdings
34
Top-10 concentration
64.9%
Key People
Form ADV owners & control persons
Christiana Goh Bardon
MANAGING MEMBER
Luke Basil Evnin
MEMBER
Ansbert K Gadicke
MANAGING MEMBER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $496.6M |
| Positions | 34 |
| Change in reported value | +29.0% |
| New positions | 10 |
| Exited positions | 7 |
| Position turnover | 41.5% |
| Top-10 concentration | 64.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
37 | $1.6B |
|
Q1 2026 13F
Filed May 15, 2026
|
41 | $1.3B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
38 | $874.0M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
40 | $610.9M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
44 | $577.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
43 | $581.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
47 | $704.4M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
43 | $666.6M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
44 | $643.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
38 | $622.0M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
32 | $427.4M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
32 | $374.6M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
34 | $496.6M |
|
Q1 2023 13F
Filed May 12, 2023
|
31 | $384.9M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
33 | $385.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
38 | $422.2M |
|
Q2 2022 13F
Filed Aug 11, 2022
|
37 | $360.0M |
|
Q1 2022 13F
Filed May 13, 2022
|
37 | $372.6M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
33 | $548.5M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
33 | $644.7M |
7 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CGEM Cullinan Oncology, Inc. | $82.3M | 16.57% |
| 2 | ISEE Iveric Bio Inc | $47.8M | 9.62% |
| 3 | KDNY Chinook Therapeutics, Inc. | $38.6M | 7.76% |
| 4 | GERN Geron Corporation | $29.5M | 5.94% |
| 5 | RETA Reata Pharmaceuticals, Inc. | $23.9M | 4.81% |
| 6 | ITOS iTeos Therapeutics, Inc. | $23.1M | 4.65% |
| 7 | NTLA Intellia Therapeutics, Inc. | $22.2M | 4.47% |
| 8 | IOVA Iovance Biotherapeutics Inc | $20.8M | 4.18% |
| 9 | RPTX Repare Therapeutics, Inc. | $17.3M | 3.49% |
| 10 | RLAY Relay Therapeutics Inc. | $17.0M | 3.43% |
| 11 | VERV Verve Therapeutics, Inc | $16.1M | 3.24% |
| 12 | MLTX Moonlake Immunotherapeutics | $15.1M | 3.03% |
| 13 | RGNX REGENXBIO Inc. | $13.1M | 2.64% |
| 14 | KRTX Karuna Therapeutics Inc | $11.6M | 2.33% |
| 15 | INSM Insmed Incorporated | $11.2M | 2.25% |
| 16 | XERS Xeris Biopharma Holdings Inc | $10.4M | 2.1% |
| 17 | MDGL Madrigal Pharmaceuticals inc | $8.8M | 1.77% |
| 18 | CRNX Crinetics Pharmaceuticals Inc. | $8.6M | 1.74% |
| 19 | TVTX Travere Therapeutics Inc. | $8.5M | 1.71% |
| 20 | RVMD Revolution Medicines, Inc. | $7.3M | 1.47% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.